Want to see ACRV full AI Analyst Report?
Acrivon Therapeutics, Inc. (ACRV) Financial Statements
Acrivon Therapeutics, Inc. Financial Overview
Acrivon Therapeutics, Inc.'s market cap is currently $71.14M. The company's EPS TTM is $-1.88; its P/E ratio is -0.88; Acrivon Therapeutics, Inc. is scheduled to report earnings on November 12, 2026, and the estimated EPS forecast is $-0.44. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 | $ 0.00 |
| Gross Profit | $ -1.36M | $ -1.01M | $ -536.00K | $ 0.00 | $ 0.00 |
| Operating Income | $ -84.11M | $ -89.20M | $ -67.24M | $ -32.66M | $ -16.18M |
| EBITDA | $ -76.55M | $ -79.55M | $ -59.85M | $ -30.80M | $ -16.21M |
| Net Income | $ -77.91M | $ -80.56M | $ -60.39M | $ -31.17M | $ -16.24M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 118.58M | $ 179.48M | $ 127.46M | $ 127.75M | $ 99.60M |
| Total Assets | $ 129.72M | $ 196.59M | $ 138.26M | $ 181.23M | $ 106.59M |
| Total Debt | $ 2.71M | $ 3.65M | $ 4.64M | $ 4.96M | $ 5.63M |
| Net Debt | $ -38.79M | $ -36.17M | $ -31.37M | $ -24.56M | $ -93.97M |
| Total Liabilities | $ 17.20M | $ 19.80M | $ 17.07M | $ 10.75M | $ 130.40M |
| Stockholders' Equity | $ 112.52M | $ 176.79M | $ 121.19M | $ 170.47M | $ -23.81M |
| Cash Flow | |||||
| Free Cash Flow | $ -65.33M | $ -68.44M | $ -43.93M | $ -32.28M | $ -14.22M |
| Operating Cash Flow | $ -63.66M | $ -65.67M | $ -42.64M | $ -30.12M | $ -13.98M |
| Investing Cash Flow | $ 66.10M | $ -51.77M | $ 50.72M | $ -141.68M | $ -238.00K |
| Financing Cash Flow | $ -749.00K | $ 121.03M | $ -1.55M | $ 101.71M | $ 112.22M |
Currency in USD